# UBS (Lux) Equity Fund – Biotech (USD)
| Most important figures |  |
| --- | --- |
|  | ISIN | 31.5.2022 | 30.11.2021 | 30.11.2020 |
| Net assets in USD |  | 496 003 604.03 | 633 683 571.43 | 1 064 223 093.72 |
| Class P-acc | LU0069152568 |  |  |  |
| Units outstanding |  | 701 719.5400 | 707 976.0440 | 1 206 348.2170 |
| Net asset value per unit in USD |  | 597.38 | 751.40 | 774.33 |
| Issue and redemption price per unit in USD 1 |  | 597.38 | 751.40 | 774.33 |
| Class (SEK) P-acc | LU1991432631 |  |  |  |
| Units outstanding |  | 96 728.2950 | 100 748.4090 | 116 391.9330 |
| Net asset value per unit in SEK |  | 746.57 | 871.00 | 845.73 |
| Issue and redemption price per unit in SEK 1 |  | 746.57 | 871.00 | 845.73 |
| Class Q-acc | LU0400035332 |  |  |  |
| Units outstanding |  | 170 030.4550 | 186 719.9040 | 351 333.7080 |
| Net asset value per unit in USD |  | 259.41 | 324.64 | 331.14 |
| Issue and redemption price per unit in USD 1 |  | 259.41 | 324.64 | 331.14 |
| Class QL-acc | LU2208649280 |  |  |  |
| Units outstanding |  | 301 399.5060 | 299 206.4890 | 21 053.2560 |
| Net asset value per unit in USD |  | 84.01 | 105.03 | 106.95 |
| Issue and redemption price per unit in USD 1 |  | 84.01 | 105.03 | 106.95 |
| 1  See note 1 |  |  |  |  |

UBS (Lux) Equity Fund – Biotech (USD) Semi-Annual Report as of 31 May 2022

## Structure of the Securities Portfolio
Geographical Breakdown as a % of net assets	
| United States | 88.55 |
| --- | --- |
| Denmark | 4.19 |
| The Netherlands | 1.91 |
| Germany | 1.25 |
| Ireland | 1.21 |
| Sweden | 0.67 |
| Switzerland | 0.37 |
| Total | 98.15 |

Economic Breakdown as a % of net assets	
| Biotechnology | 66.08 |
| --- | --- |
| Pharmaceuticals, cosmetics & medical products | 26.37 |
| Finance & holding companies | 2.62 |
| Chemicals | 1.87 |
| Miscellaneous unclassified companies | 1.21 |
| Total | 98.15 |


## Statement of Net Assets
Assets	31.5.2022
USD
Investments in securities, cost	515 818 506.35
| Investments in securities, unrealized appreciation (depreciation) | 	-28 994 338.34	 |
| --- | --- |
| Total investments in securities (Note 1) | 486 824 168.01 |
| Cash at banks, deposits on demand and deposit accounts | 9 722 650.28 |
| Receivable on subscriptions | 408 845.84 |
| Interest receivable on liquid assets | 27.21 |
| Receivable on dividends | 210 729.01 |
| Total Assets | 497 166 420.35 |
|  |  |
| Liabilities |  |
| Payable on redemptions | -275 640.43 |
| Provisions for flat fee (Note 2) | -803 482.72 |
| Provisions for taxe d’abonnement (Note 3) | -41 560.88 |
| Provisions for other commissions and fees (Note 2) | 	-42 132.29	 |
| Total provisions | -887 175.89 |
| Total Liabilities | -1 162 816.32 |
|  |  |
| Net assets at the end of the period | 496 003 604.03 |
| Statement of Operations | USD |
| Income | 1.12.2021-31.5.2022 |
| Interest on liquid assets | 0.63 |
| Dividends | 1 789 852.00 |
| Net income on securities lending (Note 10) | 68 035.10 |
| Other income (Note 4) | 188.27 |
| Total income | 1 858 076.00 |
|  |  |
| Expenses |  |
| Flat fee (Note 2) | -5 348 104.54 |
| Taxe d’abonnement (Note 3) | -141 203.50 |
| Other commissions and fees (Note 2) | -13 718.71 |
| Interest on cash and bank overdraft | -991.23 |
| Total expenses | -5 504 017.98 |
|  |  |
| Net income (loss) on investments | -3 645 941.98 |
|  |  |
| Realized gain (loss) (Note 1) |  |
| Realized gain (loss) on market-priced securities without options | -16 816 002.24 |
| Realized gain (loss) on forward foreign exchange contracts | 1 333.12 |
| Realized gain (loss) on foreign exchange | 27 707.72 |
| Total realized gain (loss) | -16 786 961.40 |
|  |  |
| Net realized gain (loss) of the period | -20 432 903.38 |
|  |  |
| Changes in unrealized appreciation (depreciation) (Note 1) |  |
| Unrealized appreciation (depreciation) on market-priced securities without options | -108 234 041.52 |
| Total changes in unrealized appreciation (depreciation) | -108 234 041.52 |
|  |  |
| Net increase (decrease) in net assets as a result of operations | -128 666 944.90 |

UBS (Lux) Equity Fund – Biotech (USD) Semi-Annual Report as of 31 May 2022
| Statement of Changes in Net Assets |  |
| --- | --- |
|  | USD |
|  | 1.12.2021-31.5.2022 |
| Net assets at the beginning of the period | 633 683 571.43 |
| Subscriptions | 42 488 762.30 |
| Redemptions | 	-51 501 784.80	 |
| Total net subscriptions (redemptions) | -9 013 022.50 |
| Net income (loss) on investments | -3 645 941.98 |
| Total realized gain (loss) | -16 786 961.40 |
| Total changes in unrealized appreciation (depreciation) | 	-108 234 041.52	 |
| Net increase (decrease) in net assets as a result of operations | -128 666 944.90 |
| Net assets at the end of the period | 496 003 604.03 |
| Development of the outstanding units |  |
|  | 1.12.2021-31.5.2022 |
| Class | P-acc |
| Number of units outstanding at the beginning of the period | 707 976.0440 |
| Number of units issued | 54 700.2440 |
| Number of units redeemed | -60 956.7480 |
| Number of units outstanding at the end of the period | 701 719.5400 |
| Class | (SEK) P-acc |
| Number of units outstanding at the beginning of the period | 100 748.4090 |
| Number of units issued | 10 403.6910 |
| Number of units redeemed | -14 423.8050 |
| Number of units outstanding at the end of the period | 96 728.2950 |
| Class | Q-acc |
| Number of units outstanding at the beginning of the period | 186 719.9040 |
| Number of units issued | 6 042.9650 |
| Number of units redeemed | -22 732.4140 |
| Number of units outstanding at the end of the period | 170 030.4550 |
| Class | QL-acc |
| Number of units outstanding at the beginning of the period | 299 206.4890 |
| Number of units issued | 22 492.6250 |
| Number of units redeemed | -20 299.6080 |
| Number of units outstanding at the end of the period | 301 399.5060 |

UBS (Lux) Equity Fund – Biotech (USD) Semi-Annual Report as of 31 May 2022

## Statement of Investments in Securities and other Net Assets as of 31 May 2022
| Description | Quantity/ | Valuation in USD | as a % |
| --- | --- | --- | --- |
|  | Nominal | Unrealized gain | of net |
|  |  | (loss) on Futures/ | assets |
|  |  | Forward |  |
|  |  | Exchange Contracts/ |  |
|  |  | Swaps (Note 1) |  |
| Transferable securities and money market instruments listed on an official stock exchange |  |  |  |
| Equities |  |  |  |
| Denmark |  |  |  |
| DKK	GENMAB AS DKK1 (BEARER) | 48 216.00 | 14 669 710.80 | 2.96 |
| DKK	H.LUNDBECK A/S DKK5 | 248 713.00 | 6 109 538.27 | 1.23 |
| Total Denmark |  | 20 779 249.07 | 4.19 |
| Germany |  |  |  |
| USD	BIONTECH SE SPON ADS EACH REP 1 ORD SHS | 37 900.00 | 6 191 344.00 | 1.25 |
| Total Germany |  | 6 191 344.00 | 1.25 |
| Ireland |  |  |  |
| USD	PROTHENA CORP PLC USD0.01 | 219 600.00 | 5 979 708.00 | 1.21 |
| Total Ireland |  | 5 979 708.00 | 1.21 |
| The Netherlands |  |  |  |
| USD	ARGENX SE SPON ADR EACH REP 1 ORD SHS | 30 623.00 | 9 471 693.90 | 1.91 |
| Total The Netherlands |  | 9 471 693.90 | 1.91 |
| Sweden |  |  |  |
| USD	OLINK HLDG AB ADS EACH REPR 1 ORD SH | 284 700.00 | 3 348 072.00 | 0.67 |
| Total Sweden |  | 3 348 072.00 | 0.67 |
| Switzerland |  |  |  |
| CHF	MOLECULAR PARTNERS CHF0.1 | 244 665.00 | 1 832 658.39 | 0.37 |
| Total Switzerland |  | 1 832 658.39 | 0.37 |
| United States |  |  |  |
| USD	ABBVIE INC COM USD0.01 | 320 181.00 | 47 185 073.97 | 9.51 |
| USD	ACADIA PHARMACEUTICALS INC COM | 493 281.00 | 7 966 488.15 | 1.61 |
| USD	AGIOS PHARMACEUTIC COM USD0.001 | 393 404.00 | 7 659 575.88 | 1.54 |
| USD	ALNYLAM PHARMACEUTICALS INC COM | 183 866.00 | 23 130 342.80 | 4.66 |
| USD	ALX ONCOLOGY HLDGS COM USD0.001 | 554 319.00 | 4 251 626.73 | 0.86 |
| USD	AMGEN INC COM USD0.0001 | 132 893.00 | 34 118 948.82 | 6.88 |
| USD	APELLIS PHARMACEUT COM USD0.0001 | 267 815.00 | 11 100 931.75 | 2.24 |
| USD	ARCUS BIOSCIENCES COM USD0.0001 | 394 272.00 | 7 471 454.40 | 1.51 |
| USD	AVANTOR INC COM USD0.01 | 289 910.00 | 9 288 716.40 | 1.87 |
| USD	BIOGEN INC COM STK USD0.0005 | 61 465.00 | 12 293 000.00 | 2.48 |
| USD	BIOMARIN PHARMA COM USD0.001 | 304 218.00 | 22 855 898.34 | 4.61 |
| USD	BLUEPRINT MEDICINE COM USD0.001 | 185 343.00 | 10 193 865.00 | 2.05 |
| USD	DENALI THERAPEUTIC COM USD0.01 | 308 290.00 | 7 488 364.10 | 1.51 |
| USD	FATE THERAPEUTICS COM USD0.001 | 298 896.00 | 6 904 497.60 | 1.39 |
| USD	GILEAD SCIENCES COM USD0.001 | 532 477.00 | 34 531 133.45 | 6.96 |
| USD	GLOBAL BLOOD THERA COM USD0.001 | 280 150.00 | 6 986 941.00 | 1.41 |
| USD	GUARDANT HEALTH IN COM USD0.00001 | 93 170.00 | 3 818 106.60 | 0.77 |
| USD	IGM BIOSCIENCES IN COM USD0.01 | 362 548.00 | 6 083 555.44 | 1.23 |
| USD	INCYTE CORPORATION COM USD0.001 | 282 511.00 | 21 439 759.79 | 4.32 |
| USD	INTELLIA THERAPEUT COM USD0.0001 | 175 236.00 | 8 085 389.04 | 1.63 |
| USD	KARUNA THERAPEUTICS INC COM USD0.0001 | 73 171.00 | 7 633 198.72 | 1.54 |
| USD	MARAVAI LIFESCIENC USD0.01 A | 275 556.00 | 8 583 569.40 | 1.73 |
| USD	MIRATI THERAPEUTIC COM NPV | 112 031.00 | 4 387 133.96 | 0.88 |
| USD	NEUROCRINE BIOSCIENCES INC COM | 189 192.00 | 17 687 560.08 | 3.56 |
| USD	NOVAVAX INC COM USD0.01(POST REV SPLIT) | 21 667.00 | 1 198 835.11 | 0.24 |
| USD	PRELUDE THERAPEUTI COM USD0.0001 | 270 000.00 | 1 134 000.00 | 0.23 |
| USD	PTC THERAPEUTICS I COM USD0.001 | 191 947.00 | 5 637 483.39 | 1.14 |
| USD	REGENERON PHARMACE COM USD0.001 | 36 236.00 | 24 087 518.64 | 4.86 |
| USD	RELAY THERAPEUTICS COM USD0.001 | 505 307.00 | 8 226 397.96 | 1.66 |
| USD	SEAGEN INC COM USD0.001 | 188 646.00 | 25 595 489.28 | 5.16 |
| USD	VERTEX PHARMACEUTI COM USD0.01 | 157 069.00 | 42 196 586.85 | 8.51 |
| Total United States |  | 439 221 442.65 | 88.55 |
| Total Equities |  | 486 824 168.01 | 98.15 |
| Total Transferable securities and money market instruments listed on an official stock exchange |  | 486 824 168.01 | 98.15 |
| Total investments in securities |  | 486 824 168.01 | 98.15 |
|  |  |  |  |
| Cash at banks, deposits on demand and deposit accounts and other liquid assets |  | 9 722 650.28 | 1.96 |
| Other assets and liabilities |  | -543 214.26 | -0.11 |
| Total net assets |  | 496 003 604.03 | 100.00 |

UBS (Lux) Equity Fund – Biotech (USD) Semi-Annual Report as of 31 May 2022

Translation (ENFR, 2022-05-31):
# UBS (Lux) Equity Fund – Biotech (USD)
| Données principales |  |
| --- | --- |
|  | ISIN | 31.5.2022 | 30.11.2021 | 30.11.2020 |
| Actif net en USD |  | 496 003 604.03 | 633 683 571.43 | 1 064 223 093.72 |
| Catégorie P-acc | LU0069152568 |  |  |  |
| Parts en circulation |  | 701 719.5400 | 707 976.0440 | 1 206 348.2170 |
| Valeur nette d’inventaire par part en USD |  | 597.38 | 751.40 | 774.33 |
| Prix d’émission et de rachat par part en USD 1 |  | 597.38 | 751.40 | 774.33 |
| Catégorie (SEK) P-acc | LU1991432631 |  |  |  |
| Parts en circulation |  | 96 728.2950 | 100 748.4090 | 116 391.9330 |
| Valeur nette d’inventaire par part en SEK |  | 746.57 | 871.00 | 845.73 |
| Prix d’émission et de rachat par part en SEK 1 |  | 746.57 | 871.00 | 845.73 |
| Catégorie Q-acc | LU0400035332 |  |  |  |
| Parts en circulation |  | 170 030.4550 | 186 719.9040 | 351 333.7080 |
| Valeur nette d’inventaire par part en USD |  | 259.41 | 324.64 | 331.14 |
| Prix d’émission et de rachat par part en USD 1 |  | 259.41 | 324.64 | 331.14 |
| Catégorie QL-acc | LU2208649280 |  |  |  |
| Parts en circulation |  | 301 399.5060 | 299 206.4890 | 21 053.2560 |
| Valeur nette d’inventaire par part en USD |  | 84.01 | 105.03 | 106.95 |
| Prix d’émission et de rachat par part en USD 1 |  | 84.01 | 105.03 | 106.95 |
| 1  Voir note 1 |  |  |  |  |


## Structure du portefeuille-titres
Répartition géographique en % de l’actif net	
| Etats-Unis | 88.55 |
| --- | --- |
| Danemark | 4.19 |
| Pays-Bas | 1.91 |
| Allemagne | 1.25 |
| Irlande | 1.21 |
| Suède | 0.67 |
| Suisse | 0.37 |
| Total | 98.15 |

Répartition économique en % de l’actif net	
| Biotechnologie | 66.08 |
| --- | --- |
| Produits pharmaceutiques, cosmétiques & médicaux | 26.37 |
| Etablissements financiers et sociétés de participation | 2.62 |
| Chimie | 1.87 |
| Diverses sociétés non classées | 1.21 |
| Total | 98.15 |

UBS (Lux) Equity Fund – Biotech (USD) Rapport semestriel au 31 mai 2022

## Etat des actifs nets
Actif	31.5.2022
USD
Portefeuille-titres, cours d’achat	515 818 506.35
| Portefeuille-titres, plus- (moins-) value non-réalisée | 	-28 994 338.34	 |
| --- | --- |
| Total portefeuille-titres (note 1) | 486 824 168.01 |
| Avoirs en banque, dépôts à vue et à terme | 9 722 650.28 |
| A recevoir sur souscriptions | 408 845.84 |
| Intérêts à recevoir sur liquidités | 27.21 |
| A recevoir sur dividendes | 210 729.01 |
| Total Actif | 497 166 420.35 |
|  |  |
| Passif |  |
| A payer sur rachats | -275 640.43 |
| Provisions pour commission de gestion forfaitaire (note 2) | -803 482.72 |
| Provisions pour taxe d’abonnement (note 3) | -41 560.88 |
| Provisions pour autres commissions et frais (note 2) | 	-42 132.29	 |
| Total des Provisions pour frais | -887 175.89 |
| Total Passif | -1 162 816.32 |
|  |  |
| Actifs nets à la fin de la période | 496 003 604.03 |
| Etat des opérations | USD |
| Revenus | 1.12.2021-31.5.2022 |
| Revenus d’intérêts sur liquidités | 0.63 |
| Dividendes | 1 789 852.00 |
| Revenus nets sur prêts de titres (note 10) | 68 035.10 |
| Autres revenus (note 4) | 188.27 |
| Total des Revenus | 1 858 076.00 |
|  |  |
| Charges |  |
| Commission de gestion forfaitaire (note 2) | -5 348 104.54 |
| Taxe d’abonnement (note 3) | -141 203.50 |
| Autres commissions et frais (note 2) | -13 718.71 |
| Charges d’intérêts sur liquidités et crédit en compte courant | -991.23 |
| Total des Charges | -5 504 017.98 |
|  |  |
| Revenus (Pertes) net(te)s des investissements | -3 645 941.98 |
|  |  |
| Bénéfices (pertes) réalisé(e)s (note 1) |  |
| Bénéfice (perte) réalisé(e) sur titres évalués à la valeur de marché hors options | -16 816 002.24 |
| Bénéfice (perte) réalisé(e) sur contrats de change à terme | 1 333.12 |
| Bénéfice (perte) réalisé(e) de change réalisé(e) | 27 707.72 |
| Total des Bénéfices (pertes) réalisé(e)s | -16 786 961.40 |
|  |  |
| Bénéfice (perte) net(te) réalisé(e) au cours de la période | -20 432 903.38 |
|  |  |
| Variations des plus- (moins-) values non-réalisées (note 1) |  |
| Plus- (Moins-) value non réalisée sur titres évalués à la valeur de marché hors options | -108 234 041.52 |
| Total des Variations des plus- (moins-) values non-réalisées | -108 234 041.52 |
|  |  |
| Augmentation/(diminution) nette de l’actif net issue de l’activité | -128 666 944.90 |

UBS (Lux) Equity Fund – Biotech (USD) Rapport semestriel au 31 mai 2022
| Variations de l’actif net |  |
| --- | --- |
|  | USD |
|  | 1.12.2021-31.5.2022 |
| Actif net au début de la période | 633 683 571.43 |
| Souscriptions | 42 488 762.30 |
| Rachats | 	-51 501 784.80	 |
| Souscriptions (Rachats) net(te)s | -9 013 022.50 |
| Revenus (Pertes) net(te)s des investissements | -3 645 941.98 |
| Total des Bénéfices (pertes) réalisé(e)s | -16 786 961.40 |
| Total des Variations des plus- (moins-) values non-réalisées | 	-108 234 041.52	 |
| Augmentation/(diminution) nette de l’actif net issue de l’activité | -128 666 944.90 |
| Actifs nets à la fin de la période | 496 003 604.03 |
| Evolution des parts en circulation |  |
|  | 1.12.2021-31.5.2022 |
| Catégorie | P-acc |
| Nombre de parts en circulation au début de la période | 707 976.0440 |
| Nombre de parts émises | 54 700.2440 |
| Nombre de parts rachetées | -60 956.7480 |
| Nombre de parts en circulation à la fin de la période | 701 719.5400 |
| Catégorie | (SEK) P-acc |
| Nombre de parts en circulation au début de la période | 100 748.4090 |
| Nombre de parts émises | 10 403.6910 |
| Nombre de parts rachetées | -14 423.8050 |
| Nombre de parts en circulation à la fin de la période | 96 728.2950 |
| Catégorie | Q-acc |
| Nombre de parts en circulation au début de la période | 186 719.9040 |
| Nombre de parts émises | 6 042.9650 |
| Nombre de parts rachetées | -22 732.4140 |
| Nombre de parts en circulation à la fin de la période | 170 030.4550 |
| Catégorie | QL-acc |
| Nombre de parts en circulation au début de la période | 299 206.4890 |
| Nombre de parts émises | 22 492.6250 |
| Nombre de parts rachetées | -20 299.6080 |
| Nombre de parts en circulation à la fin de la période | 301 399.5060 |

UBS (Lux) Equity Fund – Biotech (USD) Rapport semestriel au 31 mai 2022

## Etat du portefeuille-titres et autres actifs nets au 31 mai 2022
| Dénomination | Nombre/ | Evaluation en USD | en % |
| --- | --- | --- | --- |
|  | Nominal | Bénéfice/(perte) non | de |
|  |  | réalisé(e) sur futures/ | l’actif |
|  |  | Contrats de | net |
|  |  | change à terme/ |  |
|  |  | swaps (note 1) |  |
| Titres et instruments du marché monétaire négociés sur une bourse officielle |  |  |  |
| Actions |  |  |  |
| Danemark |  |  |  |
| DKK	GENMAB AS DKK1 (BEARER) | 48 216.00 | 14 669 710.80 | 2.96 |
| DKK	H.LUNDBECK A/S DKK5 | 248 713.00 | 6 109 538.27 | 1.23 |
| Total Danemark |  | 20 779 249.07 | 4.19 |
| Allemagne |  |  |  |
| USD	BIONTECH SE SPON ADS EACH REP 1 ORD SHS | 37 900.00 | 6 191 344.00 | 1.25 |
| Total Allemagne |  | 6 191 344.00 | 1.25 |
| Irlande |  |  |  |
| USD	PROTHENA CORP PLC USD0.01 | 219 600.00 | 5 979 708.00 | 1.21 |
| Total Irlande |  | 5 979 708.00 | 1.21 |
| Pays-Bas |  |  |  |
| USD	ARGENX SE SPON ADR EACH REP 1 ORD SHS | 30 623.00 | 9 471 693.90 | 1.91 |
| Total Pays-Bas |  | 9 471 693.90 | 1.91 |
| Suède |  |  |  |
| USD	OLINK HLDG AB ADS EACH REPR 1 ORD SH | 284 700.00 | 3 348 072.00 | 0.67 |
| Total Suède |  | 3 348 072.00 | 0.67 |
| Suisse |  |  |  |
| CHF	MOLECULAR PARTNERS CHF0.1 | 244 665.00 | 1 832 658.39 | 0.37 |
| Total Suisse |  | 1 832 658.39 | 0.37 |
| Etats-Unis |  |  |  |
| USD	ABBVIE INC COM USD0.01 | 320 181.00 | 47 185 073.97 | 9.51 |
| USD	ACADIA PHARMACEUTICALS INC COM | 493 281.00 | 7 966 488.15 | 1.61 |
| USD	AGIOS PHARMACEUTIC COM USD0.001 | 393 404.00 | 7 659 575.88 | 1.54 |
| USD	ALNYLAM PHARMACEUTICALS INC COM | 183 866.00 | 23 130 342.80 | 4.66 |
| USD	ALX ONCOLOGY HLDGS COM USD0.001 | 554 319.00 | 4 251 626.73 | 0.86 |
| USD	AMGEN INC COM USD0.0001 | 132 893.00 | 34 118 948.82 | 6.88 |
| USD	APELLIS PHARMACEUT COM USD0.0001 | 267 815.00 | 11 100 931.75 | 2.24 |
| USD	ARCUS BIOSCIENCES COM USD0.0001 | 394 272.00 | 7 471 454.40 | 1.51 |
| USD	AVANTOR INC COM USD0.01 | 289 910.00 | 9 288 716.40 | 1.87 |
| USD	BIOGEN INC COM STK USD0.0005 | 61 465.00 | 12 293 000.00 | 2.48 |
| USD	BIOMARIN PHARMA COM USD0.001 | 304 218.00 | 22 855 898.34 | 4.61 |
| USD	BLUEPRINT MEDICINE COM USD0.001 | 185 343.00 | 10 193 865.00 | 2.05 |
| USD	DENALI THERAPEUTIC COM USD0.01 | 308 290.00 | 7 488 364.10 | 1.51 |
| USD	FATE THERAPEUTICS COM USD0.001 | 298 896.00 | 6 904 497.60 | 1.39 |
| USD	GILEAD SCIENCES COM USD0.001 | 532 477.00 | 34 531 133.45 | 6.96 |
| USD	GLOBAL BLOOD THERA COM USD0.001 | 280 150.00 | 6 986 941.00 | 1.41 |
| USD	GUARDANT HEALTH IN COM USD0.00001 | 93 170.00 | 3 818 106.60 | 0.77 |
| USD	IGM BIOSCIENCES IN COM USD0.01 | 362 548.00 | 6 083 555.44 | 1.23 |
| USD	INCYTE CORPORATION COM USD0.001 | 282 511.00 | 21 439 759.79 | 4.32 |
| USD	INTELLIA THERAPEUT COM USD0.0001 | 175 236.00 | 8 085 389.04 | 1.63 |
| USD	KARUNA THERAPEUTICS INC COM USD0.0001 | 73 171.00 | 7 633 198.72 | 1.54 |
| USD	MARAVAI LIFESCIENC USD0.01 A | 275 556.00 | 8 583 569.40 | 1.73 |
| USD	MIRATI THERAPEUTIC COM NPV | 112 031.00 | 4 387 133.96 | 0.88 |
| USD	NEUROCRINE BIOSCIENCES INC COM | 189 192.00 | 17 687 560.08 | 3.56 |
| USD	NOVAVAX INC COM USD0.01(POST REV SPLIT) | 21 667.00 | 1 198 835.11 | 0.24 |
| USD	PRELUDE THERAPEUTI COM USD0.0001 | 270 000.00 | 1 134 000.00 | 0.23 |
| USD	PTC THERAPEUTICS I COM USD0.001 | 191 947.00 | 5 637 483.39 | 1.14 |
| USD	REGENERON PHARMACE COM USD0.001 | 36 236.00 | 24 087 518.64 | 4.86 |
| USD	RELAY THERAPEUTICS COM USD0.001 | 505 307.00 | 8 226 397.96 | 1.66 |
| USD	SEAGEN INC COM USD0.001 | 188 646.00 | 25 595 489.28 | 5.16 |
| USD	VERTEX PHARMACEUTI COM USD0.01 | 157 069.00 | 42 196 586.85 | 8.51 |
| Total Etats-Unis |  | 439 221 442.65 | 88.55 |
| Total des Actions |  | 486 824 168.01 | 98.15 |
| Total des Titres et instruments du marché monétaire négociés sur une bourse officielle |  | 486 824 168.01 | 98.15 |
| Total du Portefeuille-titres |  | 486 824 168.01 | 98.15 |
|  |  |  |  |
| Avoirs en banque, dépôts à vue et à terme et autres liquidités |  | 9 722 650.28 | 1.96 |
| Autres actifs et passifs |  | -543 214.26 | -0.11 |
| Total de l’Actif net |  | 496 003 604.03 | 100.00 |

UBS (Lux) Equity Fund – Biotech (USD) Rapport semestriel au 31 mai 2022